Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

NVO 45.96 +0.29 (0.63%)
price chart
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
US Pharma Sales Growth Rebounds
Of these, AbbVie Inc. (ABBV), Novo Nordisk A/S ADR (NVO), and Bayer AG ADR (BAYRY) are expected to see their revenues compound at the highest annual growth rates of 9.6%, 8.9%, and 6.1%, respectively, over the next three years starting from August ...
Stocks to Track - Novo Nordisk A/S (ADR) (NYSE:NVO), BioScrip Inc (NASDAQ ...
Birmingham, West Midlands - (TechSonian) ´┐ŻAug 09, 2014 - Novo Nordisk A/S (ADR) (NYSE:NVO) involves in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
Novo Nordisk Drops 2% On Lower Net Income Guidance
Novo Nordisk A/S (ADR) (NVO) announced second-quarter earnings yesterday for fiscal'14 (2QFY14). The Danish pharmaceutical company reported revenues of $3.87 billion (21.6 billion kroner), up 1% year-over-year (YoY), against the Street's sales ...
Related articles »  
Morning Buzz : Novo Nordisk A/S (NYSE:NVO), Bally Technologies (NYSE:BYI ...
On 1 May 2014, Novo Nordisk A/S (NYSE:NVO) initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Novo Nordisk A/S's "Neutral" Rating Reaffirmed at Zacks (NVO)
Zacks' analyst wrote, ´┐ŻNovo Nordisk reported second-quarter 2014 earnings of $0.48 per ADR, higher than the year-ago earnings of 44 cents.
Novo Nordisk A/S: Share repurchase programme
Headquartered in Denmark, Novo Nordisk employs approximately. 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Related articles »  
ADR Shares End Higher; WPP Shares Active
The chief executive of insulin-maker Novo Nordisk A/S (NVO, NOVO-B.KO) said he hasn't plans to make any big acquisitions, suggesting his company will be sitting out the frenzy of deal-making that has convulsed the global pharmaceutical industry this year.
Related articles »  
MannKind Corporation: Not Everyone's Bearish On Afrezza
Also, there are concerns that Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (ADR) (NYSE:NVO) will aggressively work to keep MannKind from successfully taking share from them in the mealtime insulin market.
Intercept Could Soon Be The Market Leader For Obesity Treatment
Other competitors with similar projects in their pipelines include Gilead Sciences, Inc. (GILD) and Novo Nordisk A/S (ADR) (NVO). Gilead's monoclonal antibody, Simtuzumab, has reached the second phase of trials, while Novo Nordisk's weight loss ...
Related articles »